Panagiota Zygoura

Comparative Assessment of Clinical Benefit Using the ESMO-Magnitude of Clinical Benefit Scale Version 1.1 and the ASCO Value Framework Net Health Benefit Score

Nathan I. Cherny, Elisabeth G.E. de Vries, Urania Dafni et al. · Journal of Clinical Oncology · 2019 · 118 citations · Full text

A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial

Ross A. Soo, Ji‐Youn Han, Urania Dafni et al. · Annals of Oncology · 2021 · 111 citations · Full text

Advanced Nsclc, Booster Trial, Novel Therapy +8

Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy – results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial

Solange Peters, Jean-Louis Pujol, Urania Dafni et al. · Annals of Oncology · 2021 · 105 citations · Full text

Oncology, Immune Checkpoint Inhibitor, Consolidation Nivolumab +6

Evaluation of NGS and RT-PCR Methods for ALK Rearrangement in European NSCLC Patients: Results from the European Thoracic Oncology Platform Lungscape Project

Igor Letovanec, Stephen P. Finn, Panagiota Zygoura et al. · Journal of Thoracic Oncology · 2017 · 84 citations · Full text

Advanced Lung Disease, European Nsclc Patients, Medicine +9

Gender-related challenges facing oncologists: the results of the ESMO Women for Oncology Committee survey

Susana Banerjee, Urania Dafni, Tamara Allen et al. · ESMO Open · 2018 · 77 citations · Full text